Unraveling the role of IgA during respiratory virus infections

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 489477

Grant search

Key facts

  • Disease

    COVID-19, Unspecified
  • start year

    2023
  • Known Financial Commitments (USD)

    $672,456.5
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Miller Matthew S
  • Research Location

    Canada
  • Lead Research Institution

    McMaster University
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

IgA is the major type of antibody found in our lungs, and the second most prevalent antibody found in blood. Despite this, the role played by IgA in mediating protection against respiratory virus infections is poorly understood. IgA, like other antibodies, can protect against viral infections in two ways. First, IgA can neutralize virus and prevent it from entering host cells. In addition, IgA bound to virus and/or virus-infected cells can be recognized by specific receptors found of the surface of certain immune cells. Upon recognition, these immune cells become stimulated to eliminate virus and virally infected cells. Mice do not naturally express receptors that recognize IgA. This has been a major barrier to understanding how interactions between IgA and immune cells contribute to protection from viral infections. Using a new mouse model that expresses the human IgA receptor (CD89), we will determine the contribution of IgA to protection against influenza virus and SARS-CoV-2. These studies will generate knowledge that will contribute to the development of new antibody-based therapeutics and better vaccines.